196 related articles for article (PubMed ID: 21553283)
1. Immunotherapy eradicates metastases with reversible defects in MHC class I expression.
Garrido C; Romero I; Berruguilla E; Cancela B; Algarra I; Collado A; García-Lora A; Garrido F
Cancer Immunol Immunother; 2011 Sep; 60(9):1257-68. PubMed ID: 21553283
[TBL] [Abstract][Full Text] [Related]
2. MHC Intratumoral Heterogeneity May Predict Cancer Progression and Response to Immunotherapy.
Romero I; Garrido C; Algarra I; Chamorro V; Collado A; Garrido F; Garcia-Lora AM
Front Immunol; 2018; 9():102. PubMed ID: 29434605
[TBL] [Abstract][Full Text] [Related]
3. Protein bound polysaccharide PSK abrogates more efficiently experimental metastases derived from H-2 negative than from H-2 positive fibrosarcoma tumor clones.
Algarra I; Collado A; Garrido F
J Exp Clin Cancer Res; 1997 Dec; 16(4):373-80. PubMed ID: 9505208
[TBL] [Abstract][Full Text] [Related]
4. Retroviral transduction of interferon-gamma cDNA into a nonimmunogenic murine fibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor.
Shiloni E; Karp SE; Custer MC; Shilyansky J; Restifo NP; Rosenberg SA; Mulé JJ
Cancer Immunol Immunother; 1993 Oct; 37(5):286-92. PubMed ID: 8402732
[TBL] [Abstract][Full Text] [Related]
5. Selective upregulation of MHC class I expression in metastatic colonies derived from tumor clones of a murine fibrosarcoma.
Pedrinaci S; Algarra I; Garcia Lora A; Gaforio JJ; Perez M; Garrido F
Int J Clin Lab Res; 1999; 29(4):166-73. PubMed ID: 10784379
[TBL] [Abstract][Full Text] [Related]
6. Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations.
Aptsiauri N; Carretero R; Garcia-Lora A; Real LM; Cabrera T; Garrido F
Cancer Immunol Immunother; 2008 Nov; 57(11):1727-33. PubMed ID: 18491093
[TBL] [Abstract][Full Text] [Related]
7. MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components.
Garcia-Lora A; Martinez M; Algarra I; Gaforio JJ; Garrido F
Int J Cancer; 2003 Sep; 106(4):521-527. PubMed ID: 12845647
[TBL] [Abstract][Full Text] [Related]
8. Local secretion of IFN-gamma induces an antitumor response: comparison between T cells plus IL-2 and IFN-gamma transfected tumor cells.
Sadanaga N; Nagoshi M; Lederer JA; Joo HG; Eberlein TJ; Goedegebuure PS
J Immunother; 1999 Jul; 22(4):315-23. PubMed ID: 10404433
[TBL] [Abstract][Full Text] [Related]
9. "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy.
Garrido F; Cabrera T; Aptsiauri N
Int J Cancer; 2010 Jul; 127(2):249-56. PubMed ID: 20178101
[TBL] [Abstract][Full Text] [Related]
10. A weakly tumorigenic phenotype with high MHC class-I expression is associated with high metastatic potential after surgical removal of the primary murine fibrosarcoma.
Pérez M; Algarra I; Ljunggren HG; Caballero A; Mialdea MJ; Gaforio JJ; Klein G; Kärre K; Garrido F
Int J Cancer; 1990 Aug; 46(2):258-61. PubMed ID: 2116997
[TBL] [Abstract][Full Text] [Related]
11. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
12. H-2 antigens and tumour-associated transplantation antigens in clones derived from a methylcholanthrene-induced BALB/c tumour: their influence on the generation in vitro and in vivo of the specific anti-tumour immune response.
Pérez M; Garrido A; Algarra I; Caballero A; Delgado C; Collado MD; Fernández-Cruz E; Garrido F
Exp Clin Immunogenet; 1989; 6(3):204-18. PubMed ID: 2631798
[TBL] [Abstract][Full Text] [Related]
13. Polysaccharide-K augments docetaxel-induced tumor suppression and antitumor immune response in an immunocompetent murine model of human prostate cancer.
Wenner CA; Martzen MR; Lu H; Verneris MR; Wang H; Slaton JW
Int J Oncol; 2012 Apr; 40(4):905-13. PubMed ID: 22159900
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor reactivity of tumor-sensitized T cells by interferon alfa.
Vander Woude DL; Wagner PD; Shu S; Chang AE
Arch Surg; 1991 Mar; 126(3):307-13. PubMed ID: 1998472
[TBL] [Abstract][Full Text] [Related]
15. Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells.
Wang LX; Shu S; Plautz GE
Cancer Res; 2005 Oct; 65(20):9547-54. PubMed ID: 16230420
[TBL] [Abstract][Full Text] [Related]
16. Recruitment of host CD8+ T cells by tumor-infiltrating lymphocytes and recombinant interleukin-2 during adoptive immunotherapy of cancer.
Burger UL; Chang MP; Goedegebuure PS; Eberlein TJ; Adams-Hodgins S
Surgery; 1995 Mar; 117(3):325-33. PubMed ID: 7878540
[TBL] [Abstract][Full Text] [Related]
17. Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype.
Garrido F; Romero I; Aptsiauri N; Garcia-Lora AM
Int J Cancer; 2016 Jan; 138(2):271-80. PubMed ID: 25471439
[TBL] [Abstract][Full Text] [Related]
18. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
[TBL] [Abstract][Full Text] [Related]
19. Effect of interleukin-1 alpha on the in vitro activation of tumor-draining lymph node cells for adoptive immunotherapy.
Hammel JM; Tuck MK; Hain JM; Chang AE; Sondak VK
J Immunother Emphasis Tumor Immunol; 1994 Jul; 16(1):1-12. PubMed ID: 8081555
[TBL] [Abstract][Full Text] [Related]
20. Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants.
Garcia-Lora A; Algarra I; Gaforio JJ; Ruiz-Cabello F; Garrido F
Int J Cancer; 2001 Jan; 91(1):109-19. PubMed ID: 11149409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
